Source link here.
If forced to let yourself be vaccined: Demand AstraZeneca's MedImmune, which is administered nasally – not per injection, whereby you avoid the squalene induced Gulf War Syndrome and thimerosal effects!

Europeans – do wake up now!
Der Spiegel 7. Aug. 2009: This is a heretofore unseen experiment on the Europeans. Of the 25 million German citizens to be vaccinated in the first stage, close to 250,000 could suffer a serious reaction to the vaccine, but there are virtually no data on the effects of a new adjuvant — a component used to stretch the active ingredient — used in the GSK vaccine on pregnant women.The Novartis vaccine grows on dog cells, which can cause tumors in animal experiments. The US agency charged with regulating drugs, the Food and Drug Administration (FDA), has thus far refused to approve flu vaccines containing adjuvants.
It is only too convenient for drug companies when new vaccines and production processes to combat swine flu are tested on millions of Europeans. Indeed, instead of having to pay for testing, the drug companies stand to profit handsomely from this approach.

This blog has previously pointed to the dangers of upcoming flu mass vaccinations like: Contamination with live bird flu virus and squalene, and here, causing the Gulf War Syndrome, thimerosal causing autism in children – and heavy cell damage in fetuses.This article will point to yet another danger: Increasing virulence of the flu virus due to mass vaccinations. Besides, it will point to the fact that National Health Organisations and the WHO continues to neglect the dangers of squalene and thimerosal.

Additional SAGE discussions WHOs report 24 July, 2009, 84, 301–308 - No 30 p.303
“Oil-in-water adjuvanted vaccines have been shown to induce broader immunity and to reduce required antigen levels (“antigen-sparing”) for other influenza viruses, and this seemed likely to be the case for pandemic influenza A (H1N1) viruses.”

How the flu vaccine is prepared
The European Medicines Agency´s Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the Agency's opinions on all questions concerning. There are two ways vaccine manufacturers can obtain an authorisation:
1. Using the ‘mock-up’ vaccine approach. A mock-up pandemic influenza vaccine is a vaccine that is prepared in advance of a future pandemic influenza, using a strain that could cause a pandemic, but before knowing the actual virus strain that will cause the pandemic. Companies carry out full studies of the quality, safety and efficacy of the mock-up vaccine with the original virus strain. Once the pandemic virus strain is known, it is used to replace the original strain in the vaccine. The original studies can be used to predict how people will react to the vaccine once the flu strain causing the pandemic has been included.
2. Developing a new vaccine ‘from scratch’. This will require a new, full marketing authorisation and therefore more data than the mock-up approach. The Agency is currently working with two manufacturers towards the authorisation of new pandemic vaccines

This blog has previously pointed to the dangers of upcoming flu mass vaccinations like: Contamination with live bird flu virus and squalene, and here, causing the Gulf War Syndrome, thimerosal causing autism in children – and heavy cell damage in fetuses.This article will point to yet another danger: Increasing virulence of the flu virus due to mass vaccinations. Besides, it will point to the fact that National Health Organisations and the WHO continues to neglect the dangers of squalene and thimerosal.

Additional SAGE discussions WHOs report 24 July, 2009, 84, 301–308 - No 30 p.303
“Oil-in-water adjuvanted vaccines have been shown to induce broader immunity and to reduce required antigen levels (“antigen-sparing”) for other influenza viruses, and this seemed likely to be the case for pandemic influenza A (H1N1) viruses.”

How the flu vaccine is prepared
The European Medicines Agency´s Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the Agency's opinions on all questions concerning. There are two ways vaccine manufacturers can obtain an authorisation:
1. Using the ‘mock-up’ vaccine approach. A mock-up pandemic influenza vaccine is a vaccine that is prepared in advance of a future pandemic influenza, using a strain that could cause a pandemic, but before knowing the actual virus strain that will cause the pandemic. Companies carry out full studies of the quality, safety and efficacy of the mock-up vaccine with the original virus strain. Once the pandemic virus strain is known, it is used to replace the original strain in the vaccine. The original studies can be used to predict how people will react to the vaccine once the flu strain causing the pandemic has been included.
2. Developing a new vaccine ‘from scratch’. This will require a new, full marketing authorisation and therefore more data than the mock-up approach. The Agency is currently working with two manufacturers towards the authorisation of new pandemic vaccines

All mock-up vaccines have been prepared with an H5N1 strain of flu virus that needs to be changed now to the H1N1 strain that is causing the current pandemic.
This variation will be processed quickly, normally within five days. Once theCHMP has given a positive opinion, the variation can then be approved by the European Commission and the vaccine can be made available for use.